Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 14, 2026
TickeronGET DAILY SIGNALS
Tvardi Therapeutics (TVRD): Tracking Clinical Catalysts and Funding Dynamics

Tvardi Therapeutics (TVRD): Tracking Clinical Catalysts and Funding Dynamics

Key Takeaways

  • Hepatocellular carcinoma (HCC) readout ahead: Topline data from the Phase 1b/2 REVERT LIVER CANCER study of TTI-101 are expected in early 2027, representing the single most important near-term catalyst for the stock forecast.
  • TTI-109 represents a potential strategic pivot: The oral prodrug of TTI-101 is designed to improve gastrointestinal tolerability, addressing a key limitation that weighed on earlier trials, with Phase 1 healthy-volunteer data anticipated in 2026.
  • Capital position and funding sensitivity: Management has guided that existing cash is expected to fund operations into the third quarter of 2027, making capital-raising terms and potential partnership activity central to the future outlook.
  • Industry tailwinds in targeted oncology: A validated but historically "undruggable" target (STAT3) and regulatory designations such as Fast Track and orphan drug status position the company within high-unmet-need disease areas.
  • Key macro sensitivity: As a pre-revenue clinical-stage biotech, the company is highly sensitive to financing conditions, interest rates, and biotech sector risk appetite rather than to consumer demand cycles.
  • Analyst sentiment and risks: Consensus views hinge on binary clinical data and funding milestones; a failed trial, delays, or dilutive financing could materially alter the outlook.

Strategic Positioning in a Competitive Landscape

TVRD is a clinical-stage biopharmaceutical company focused on oral, small-molecule inhibitors of STAT3, a transcription factor that has long been considered biologically validated yet historically difficult to drug. Its lead candidate, TTI-101, is in Phase 2 development for hepatocellular carcinoma (HCC), the most common form of primary liver cancer, while its second candidate, TTI-109, is an oral prodrug engineered to convert to TTI-101 in the bloodstream while reducing exposure of the active drug to the intestinal lining.

This differentiated mechanism and convenient oral dosing form the foundation of the company's market positioning. In oncology, oral STAT3 inhibition could offer a meaningful alternative to injectable immunotherapies and tyrosine kinase inhibitors if efficacy and tolerability are confirmed. The company holds U.S. orphan drug designations for TTI-101 in both IPF and HCC, as well as a Fast Track designation for HCC, which could support accelerated regulatory pathways if development succeeds. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Structurally, TVRD remains early-stage and pre-revenue, competing against large, well-capitalized biopharmaceutical companies in both fibrosis and liver-cancer indications. Its medium-term positioning will depend less on market-share trends and more on its ability to generate positive clinical data, secure non-dilutive or partner-based funding, and preserve its intellectual-property position.

Major Catalysts on the Horizon

The most consequential upcoming event is the release of topline data from the Phase 1b/2 REVERT LIVER CANCER study of TTI-101 in HCC, which management has guided to early in the first quarter of 2027. Positive results could significantly reshape investor sentiment and potentially attract partnership interest, while disappointing data would likely pressure the stock.

In parallel, Phase 1 data for TTI-109 in healthy volunteers are expected during 2026. Because TTI-109 is designed specifically to improve gastrointestinal tolerability, a favorable readout could position the program for expansion into inflammatory and fibrotic indications. Management has indicated an intent to initiate a clinical trial of TTI-109 in ulcerative colitis in 2027, subject to IND clearance and additional funding.

Capital-allocation decisions are an equally important catalyst. With a guided cash runway into the third quarter of 2027, the company will likely need to raise additional capital or enter strategic collaborations to fund later-stage development. From what I see, analyst ratings in this context tend to be binary and event-driven.

Industry and Macroeconomic Influences

TVRD's trajectory is shaped primarily by the dynamics of the biotechnology financing cycle and the oncology drug-development landscape. Interest rates and overall risk appetite in equity markets directly influence the availability and cost of capital for pre-revenue developers, making rate policy a meaningful external variable for the stock forecast.

Inflationary pressure on clinical-trial and manufacturing costs can affect the rate at which cash is consumed. On the demand side, the long-term rise in HCC incidence globally supports a structurally growing addressable market, though intensifying competition from established checkpoint inhibitors means any eventual approval would face a crowded therapeutic landscape.

2026 Outlook and Long-Term Themes

Looking toward 2026 and beyond, the dominant long-term theme is whether TVRD can convert a scientifically differentiated platform into de-risked clinical data. The HCC readout in early 2027 and the TTI-109 Phase 1 results in 2026 will be pivotal in determining whether the pipeline advances into registrational trials or pivots toward new indications such as ulcerative colitis.

Cost-structure evolution remains a secondary but meaningful consideration. As a pre-revenue company, TVRD currently generates no operating margins; the relevant question is capital efficiency. Competitive threats from large pharmaceutical companies, coupled with the inherent risk of clinical failure, remain the principal long-term risks.

Exploring AI Tools for Market Insights

One tool I’ve found helpful for assessing directional signals in names like this is Tickeron’s AI Trend Prediction Engine. It offers searchable prediction categories, historical context, and alert-oriented functionality that can complement fundamental analysis when evaluating potential breakouts or reversals across a range of assets.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TVRD

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


TVRD in +64.09% Uptrend, rising for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TVRD advanced for three days, in 185 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TVRD as a result. In 66 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for TVRD just turned positive on October 15, 2026. Looking at past instances where TVRD's MACD turned positive, the stock continued to rise in 29 of 36 cases over the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The 10-day RSI Indicator for TVRD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 28 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 55 cases where TVRD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

TVRD moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

TVRD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TVRD entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.524) is normal, around the industry mean (3.592). P/E Ratio (-0.334) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. TVRD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TVRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
3 Sugar Creek Center boulevard
Phone
+1 713 489-8654
Employees
12
Web
https://www.tvarditherapeutics.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.